Patents by Inventor Bradley J. Heidrich

Bradley J. Heidrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GPRC5D CHIMERIC ANTIGEN RECEPTORS AND CELLS EXPRESSING THE SAME
    Publication number: 20200231686
    Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
    Type: Application
    Filed: January 15, 2020
    Publication date: July 23, 2020
    Inventors: Ricardo Attar, Rajkumar Ganesan, Francois Gaudet, Bradley J. Heidrich, Carmen Baca Jones, John Lee, Yingzhe Li, Sanjaya Singh, Sathya Venkataramani
  • ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF
    Publication number: 20190270826
    Abstract: Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor IL1RAP-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with IL1RAP-expressing cancer and thus may be amenable to treatment with an IL1RAP-specific anti-cancer therapeutic, such as the multi specific antibodies against IL1RAP and CD3 described herein.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 5, 2019
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Bradley J. Heidrich, Jennifer F. Nemeth, Walter K. Nishioka, JR., Thai Dinh, Rosa Maria Fernandes Cardoso, Ricardo Marcos Attar, Francois Gaudet, Mark E. Salvati
  • ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF
    Publication number: 20170121420
    Abstract: Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor IL1RAP-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with IL1RAP-expressing cancer and thus may be amenable to treatment with an IL1RAP-specific anti-cancer therapeutic, such as the multispecific antibodies against IL1RAP and CD3 described herein.
    Type: Application
    Filed: November 1, 2016
    Publication date: May 4, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Bradley J. Heidrich, Jennifer F. Nemeth, Walter K. Nishioka, Jr., Thai Dinh, Rosa Maria Fernandes Cardoso, Darlene Pizutti, Brandy Strake, Jamie Fisher, Ricardo Marcos Attar, Francois Gaudet, Mark E. Salvati